56 Views | 33 Downloads
John S. Klassen, john.klassen@ualberta.ca. Telephone: (780) 492-3501. Fax: (780) 492-8231.
The authors acknowledge the Natural Sciences and Engineering Research Council of Canada (J.S.K.), the Canada Foundation for Innovation (J.S.K.), the Alberta Innovation and Advanced Education Research Capacity Program (J.S.K.), Canadian Institutes of Health Research (Y.S.P., D.C., N.D.), the Consortium Québécois pour le Recherche sur le Médicament (Y.S.P., D.C., N.D.), and the Canada Excellence Research Chairs (L.K.M.) Program for generous funding. The authors thank Professors T. Lowary (University of Alberta) for the B trisaccharide neoglycolipid and C. Cairo (University of Alberta) for the carbohydrate recognition domain of human galectin 3. Plasmids for expression of SARS-CoV-2 S protein and RBD proteins were generously provided by F. Krammer (Icahn School of Medicine at Mount Sinai, produced under NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C). This project was funded in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under contract no. HHSN272201400004C (S.M.T.).
The authors declare no competing financial interest.
© 2022 The Authors. Published by American Chemical Society